Vascular Biogenics Ltd (VBLT)

[gr8db8]

Here you go, Oren: http://www.abstractsonline.com/pp8/#!/4277/presentation/151

Interesting that Avastin achieved 10 months mOS in this trial. It historically has achieved 8 months (32 weeks).

Nivo's 9.8 months (39 weeks) would have beaten Avastin's 32 weeks but in this case, Avastin performed better than usual. VB-111's mOS was 59 weeks in Ph2 so that is still significant if it is repeated in Ph3.